Kiora Pharmaceuticals(KPRX) - 2025 Q1 - Quarterly Results

development milestones related to KIO-301 could further strengthen our cash position and extend our runway even longer." First Quarter Financial Highlights Exhibit 99.1 Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 Encinitas, California – May 9, 2025 - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced first quarter 2025 financi ...